Sunvozertinib Receives Accelerated FDA Approval for EGFR Exon 20-Mutant Lung Cancer

Sunvozertinib (Zegfrovy, Dizal Pharmaceutical), on July 2, 2025, was approved by the FDA for EGFR exon 20 insertion mutation-positive patients with disease progressing after platinum-based chemotherapy in locally advanced or metastatic non-small-cell lung cancer (NSCLC), through accelerated approval . This approval provides patients progressing after platinum-based chemotherapy with a second-line treatment option.

EGFR exon 20 insertion mutationsaccount for approximately 4–12% of EGFR mutations seen in NSCLC. This mutation type is detected in approximately 2% to 3% of all NSCLC patients.

Previously, in this mutation group, the FDA had granted accelerated approval only to the monoclonal antibody amivantamab-vmjw (Rybrevant) in 2021. Another oral agent, mobosertinib (Exkivity) , received similar approval in 2021 but was voluntarily withdrawn by its manufacturer in 2024 after confirmatory trials failed to demonstrate the expected clinical benefit. Thus, sunvozertinibentered practice in exon 20 insertion-mutated NSCLC after platinum chemotherapy as the second FDA-approved targeted treatment .

📊 Comparison Table

Scientific Basis for FDA Approval: WU-KONG1B

Supporting sunvozertinib's FDA approval, WU-KONG1B is a clinical trial in NSCLC specifically designed for patients carrying an EGFR exon 20 insertion mutation , conducted as a phase 1/2, open-label, multicenter, multiarm study.

It evaluated patients progressing after platinum-based chemotherapywith metastatic or locally advanced EGFR exon 20 insertion-mutated disease: 85 NSCLC patients.

Key Data (Phase 2):

These findings are considered a meaningful clinical advance for NSCLC patients with EGFR exon 20 insertion mutations.

Who Is Sunvozertinib Suitable For?

FDA-approved sunvozertinib is for locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations confirmed by an FDA-approved diagnostic test, after progression on platinum-containing chemotherapy.

The FDA simultaneously approved the Oncomine Dx Express Test to identify EGFR exon 20 insertion mutations in potential sunvozertinib candidates.

Side Effects Requiring Attention

Potential adverse effects requiring attention include:

• Interstitial lung disease or pneumonitis
• Gastrointestinal adverse effects
• Dermatological adverse effects
• Ocular toxicity
• Embryo-fetal toxicity risk

Regular monitoring for these potential effects is important during treatment.

Why Does It Matter?

Patients with EGFR exon 20 insertion mutations frequently resist existing EGFR inhibitors. Targeted treatments for this specific group are therefore critical for extending survival and improving quality of life. Sunvozertinib's FDA approval marks the beginning of a new treatment era for these patients.

This development again demonstrates personalized medicine's power in NSCLC and opens the way to more innovative options for this mutation group in the coming years.